Drug information provided by: Merative, Micromedex®
Zanubrutinib is used to treat mantle cell lymphoma (MCL) in patients who have received at least one previous treatment for their cancer. This medicine is also used to treat Waldenström macroglobulinemia (WM). It is also used to treat marginal zone lymphoma (MZL) that has come back (relapsed) or did not respond to the treatment (refractory) in patients who have received at least one previous treatment (eg, anti-CD20-based treatment). This medicine is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Zanubrutinib is also used in combination with obinutuzumab to treat follicular lymphoma (FL) that has come back or did not respond to the treatment in patients who have received at least 2 previous treatments.
Zanubrutinib is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: July 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.